Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Baxter International (NY:BAX)

22.93 +0.18 (+0.79%)
Official Closing Price Updated: 7:00 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Baxter International

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Baxter Completes Acquisition of Hillrom, Creating ~$15 Billion Global Medtech Leader
From Baxter International Inc.
Via Business Wire
Baxter Presents Data at ASHP Meeting Indicating Machine Learning May Enhance Infusion Pump Programming Safety
From Baxter International Inc.
Via Business Wire
Mr. Market Will Shop ‘til He Drops!
Via Talk Markets
Baxter Declares Quarterly Dividend
From Baxter International Inc.
Via Business Wire
Stock Profile: Baxter International Inc.
Baxter International reported second-quarter sales increased a healthy 14% to $3.1 billion with net income increasing 22% to $301 million and EPS jumping 23% to $0.59. 
Via Talk Markets
Baxter Named to Dow Jones Sustainability Indices in Recognition of Continued Commitment to Corporate Responsibility
From Baxter International Inc.
Via Business Wire
Baxter Announces $100 Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility
From Baxter International Inc.
Via Business Wire
Here Are Answers for Shareholders After General Electric Breaks Up
Larry Culp was hired to save GE in 2018, but finally decided to break it up in order to unlock what's left of its value, especially in the healthcare unit. 
Via InvestorPlace
Baxter Highlights New Data Indicating Sharesource Digital Health Platform for Home Dialysis May Improve Survival and Reduce Hospitalizations
From Baxter International Inc.
Via Business Wire
Baxter to Present at Evercore ISI 4th Annual HealthCONx Conference
From Baxter International Inc.
Via Business Wire
Baxter International Inc (BAX) Q2 2021 Earnings Call Transcript
BAX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Baxter Shares Fall Despite Better-Than-Expected Q3 Earnings, FY21 EPS Outlook Boost
Baxter International Inc (NYSE: BAX) posted Q3 revenue of $3.23 billion, in line with the consensus, up 9% on a reported basis, 7% on a constant currency basis, and 6%... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
Baxter Reports Third-Quarter 2021 Results
From Baxter International Inc.
Via Business Wire
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury
From Baxter International Inc. and bioMérieux
Via Business Wire
Baxter to Present at Credit Suisse 30th Annual Virtual Healthcare Conference
From Baxter International Inc.
Via Business Wire
Baxter Presents Critical Care Data at 34th Annual European Society of Intensive Care Medicine LIVES Congress
From Baxter International Inc.
Via Business Wire
Baxter to Host Third-Quarter 2021 Financial Results Conference Call for Investors
From Baxter International Inc.
Via Business Wire
Baxter's Norepinephrine Wins FDA Nod For Low Blood Pressure
The FDA has approved Baxter International Inc's (NYSE: BAX) premix norepinephrine bitartrate in 5% dextrose injection. Norepinephrine is indicated to raise blood pressure in... 
Via Benzinga
Baxter Announces U.S. FDA Approval and Launch of Ready-to-use Cardiovascular Medicine Norepinephrine in Premix Formulation
From Baxter International Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 3, 2021
Upgrades Barclays upgraded the previous rating for Baxter International Inc (NYSE: 
Via Benzinga
Price To Earnings Ratio Insights For Baxter Intl
Looking into the current session, Baxter Intl Inc. (NYSE:BAX) shares are trading at $82.22, after a 5.95% rise. Moreover, over the past month, the stock spiked by 10... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021
Upgrades For Bank of America Corp (NYSE: 
Via Benzinga
Baxter to Acquire Hillrom At $156/Share: See The Highlights
Baxter International Inc (NYSE: BAX) has agreed to acquire Hill-Rom Holdings Inc (NYSE: HRC) for $156.00 per share in cash, slightly higher than the earlier... 
Via Benzinga
Baxter to Acquire Hillrom, Expanding Connected Care and Medical Innovation Globally
From Baxter International Inc.
Via Business Wire
2 Little-Followed Stocks That Are Soaring Monday
Markets were on the rise overall, but these companies were surprising in their gains. 
Via The Motley Fool
Topics Stocks
Why Shares of Hill-Rom Holdings Are Surging This Morning
A previous buyout offer gets raised. 
Via The Motley Fool
Baxter In Advanced Talks For $10B Hill Rom Buyout: WSJ
The Wall Street Journal reported that Baxter International Inc (NYSE: BAX) is reportedly in advanced talks to Hill-Rom Holdings Inc (NYSE: HRC) for... 
Via Benzinga
Baxter International Inc (BAX) Under Pressure, Here’s The Trade
Baxter International Inc stock is now trading below its 200-week moving average. This puts the stock in a weak technical position on the charts and indicates lower stock prices ahead. 
Via Talk Markets
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.